NF1 Is a Tumor Suppressor in Neuroblastoma that Determines Retinoic Acid Response and Disease Outcome-Reference-Cited by-同舟云学术

NF1 Is a Tumor Suppressor in Neuroblastoma that Determines Retinoic Acid Response and Disease Outcome

Published:2010-07 Issue:2 Volume:142 Page:218-229
ISSN:0092-8674
Container-title:Cell
language:en
Short-container-title:Cell

Author:

Hölzel Michael,Huang Sidong,Koster Jan,Øra Ingrid,Lakeman Arjan,Caron Huib,Nijkamp Wouter,Xie Jing,Callens Tom,Asgharzadeh Shahab,Seeger Robert C.,Messiaen Ludwine,Versteeg Rogier,Bernards René

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference48 articles.

1. Activation of the Ras-ERK pathway inhibits retinoic acid-induced stimulation of tissue transglutaminase expression in NIH3T3 cells;Antonyak;J. Biol. Chem.,2003

2. Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification;Asgharzadeh;J. Natl. Cancer Inst.,2006

3. Chromosome 1p and 11q deletions and outcome in neuroblastoma;Attiyeh;N. Engl. J. Med.,2005

4. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia;Bentires-Alj;Cancer Res.,2004

5. A large-scale RNAi screen in human cells identifies new components of the p53 pathway;Berns;Nature,2004

Cited by 175 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting SWI/SNF ATPases reduces neuroblastoma cell plasticity;The EMBO Journal;2024-08-22

2. KLF7 promotes neuroblastoma differentiation through the GTPase signaling pathway by upregulating neuroblast differentiation‐associated protein AHNAKs and glycerophosphodiesterase GDPD5;The FEBS Journal;2024-06-26

3. Preclinical Therapeutic Efficacy of RAF/MEK/ERK and IGF1R/AKT/mTOR Inhibition in Neuroblastoma;Cancers;2024-06-25

4. Direct Synthesis of α- and β-2′-Deoxynucleosides with Stereodirecting Phosphine Oxide via Remote Participation;Journal of the American Chemical Society;2024-03-14

5. Therapeutically Actionable Genetic Aberrations;Pediatric Oncology;2024